Mineralys Therapeutics (MLYS) announced detailed results from the Phase 2 Advance-HTN trial, one of two pivotal trials evaluating lorundrostat ...

We recently compiled a list of the 10 Pump and Dump Stocks Favored by Hedge Funds. In this article, we are going to take a ...

Stocks Leading in March. In this article, we are going to take a look at where Mineralys Therapeutics, Inc. (NASDAQ:MLYS) ...

The addition of the aldosterone synthase inhibitor helps patients with resistant hypertension lower their blood pressure.

BofA Securities, Evercore ISI, Goldman Sachs & Co. LLC, Stifel and Wells Fargo Securities acted as joint book-running managers for the offering. LifeSci Capital acted as lead manager and H.C.

Mineralys Therapeutics, Inc. RADNOR, Pa., March 10, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines ...

Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing treatments for conditions related to dysregulated aldosterone, announced it will host a conference ...

Mineralys Therapeutics, Inc. has a 1 year low of $8.24 and a 1 year high of $18.38. The firm has a market cap of $1.01 billion, a price-to-earnings ratio of -4.44 and a beta of 1.50.

In this article, we are going to take a look at where Mineralys Therapeutics, Inc. (NASDAQ:MLYS) stands against other stocks that are receiving the most insider investment in March. “The economy ...

RADNOR, PA — Mineralys Therapeutics, Inc. (NASDAQ: MLYS) has announced an upcoming conference call and webinar to highlight ...

March 10 (Reuters) - Mineralys Therapeutics (MLYS.O), opens new tab said on Monday its lead drug significantly lowered blood pressure in patients with difficult-to-treat hypertension in late- and ...